Table 1. Characteristics of patients at baseline.
| Non-Elevated Troponin | Elevated Troponin | p-value | Missing values (%) | |
|---|---|---|---|---|
| N | 229 | 91 | ||
| Sex = Male (%) | 155 (67.7) | 50 (54.9) | 0.044 | 0 |
| Age- years (median [IQR a]) | 59.83 [49.65, 71.19] | 73.31 [61.33, 82.25] | <0.001 | 0 |
| No cardiac comorbidity b- no. (%) | 192 (83.8) | 52 (57.1) | <0.001 | 0 |
| Atrial Fibrillation- no. (%) | 17 (7.4) | 19 (20.9) | 0.001 | 0 |
| Heart Failure- no. (%) | 10 (4.4) | 17 (18.7) | <0.001 | 0 |
| Ischemic Heart Disease- no. (%) | 21 (9.2) | 22 (24.2) | 0.001 | 0 |
| Chronic Kidney Disease- no. (%) | 19 (8.3) | 20 (22.0) | 0.001 | 0 |
| Hypertension- no. (%) | 84 (36.7) | 54 (59.3) | <0.001 | 0 |
| Cerebrovascular Accident- no. (%) | 17 (7.4) | 12 (13.2) | 0.16 | 0 |
| Chronic Obstructive Pulmonary Disease- no. (%) | 4 (1.7) | 7 (7.7) | 0.022 | 0 |
| Diabetes Mellitus- no. (%) | 53 (23.1) | 30 (33.0) | 0.095 | 0 |
| Dyslipidemia- no. (%) | 71 (31.0) | 34 (37.4) | 0.337 | 0 |
| Malignancy- no. (%) | 24 (10.5) | 15 (16.5) | 0.197 | 0 |
| ACEI c / ARB d Therapy- no. (%) | 21 (9.2) | 15 (16.5) | 0.095 | 0 |
| BB e Therapy- no. (%) | 42 (18.3) | 39 (42.9) | <0.001 | 0 |
| HMG CoA reductase inhibitors Therapy- no. (%) | 68 (29.7) | 40 (44.0) | 0.021 | 0 |
| Temperature- celsius (median [IQR a]) | 38.00 [37.30, 38.60] | 38.10 [37.20, 38.70] | 0.899 | 0 |
| SBP f, g –mmHgh (median [IQR a]) | 111.00 [101.00, 122.00] | 105.00 [85.00, 122.00] | 0.004 | 0 |
| Creatinine g- mg/dl (median [IQR a]) | 0.89 [0.71, 1.12] | 1.02 [0.80, 1.39] | <0.001 | 0 |
| Albumin g - g/dl (median [IQR a]) | 3.80 [3.60, 4.10] | 3.50 [3.20, 3.80] | <0.001 | 2.2 |
| Hemoglobin g - g/dl (median [IQR a]) | 13.65 [12.45, 14.60] | 12.70 [11.65, 14.20] | 0.003 | 0 |
| Lymphocytes g K/μl (median [IQR a]) | 1.02 [0.74, 1.41] | 0.87 [0.60, 1.28] | 0.028 | 0 |
| Platelets g - K/μl (median [IQR a]) | 184.00 [141.00, 234.00] | 198.00 [152.00, 264.50] | 0.04 | 0 |
| CRP h, g- mg/l (median [IQR a]) | 64.24 [26.32, 128.92] | 92.67 [37.67, 168.22] | 0.05 | 1.2 |
a interquartile range
b Including atrial fibrillation, heart failure or ischemic heart disease
c angiotensin-converting-enzyme inhibitors
d angiotensin II receptor blocker
e beta-blockers
f systolic blood pressure
g Measured within 24-hours from admission.
h millimeter of mercury
i c-reactive protein.